Intriguingly, expression of MHC genes on MM cells has recently been implicated in the efficacy of anti-BCMA bispecific T-cell engaging (TCE) antibody therapy, as a likely required factor enabling T-cell mediated MM killing [13]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.